Similarly, it has been demonstrated that c-Met expression increased in pancreatic ductal adenocarcinoma, suggesting that c-Met might be a molecular marker for predicting prognosis in patients with pancreatic cancer (Zhu et al., 2011). The gene discussed is MET; the disease is pancreatic ductal adenocarcinoma.